Ipca Laboratories (IPCALAB) Q3 25/26 earnings summary

Executive summary

• Domestic business grew 12% in Q3 FY26, outpacing the Indian pharma market (IPM) growth of 8.9%.

• Export formulations grew 17% in Q3 and 6% for the nine months, while API business was flat for the quarter but up 14% for nine months.

• Standalone net total income for Q3 FY26 rose 11% YoY to Rs. 1,863.00 crores; consolidated net total income increased 7% to Rs. 2,412.69 crores.

• Standalone net profit for Q3 FY26 was Rs. 303.45 crores, up 13%; consolidated net profit was Rs. 326.27 crores, up 31%.

• Consolidated business grew 6.5% in Q3 and 8.44% for the nine months, with improved EBITDA margins.

Financial highlights

• Q3 consolidated revenue: INR 2,245 crore, up 6.5% YoY; nine months revenue: INR 7,258 crore, up 8.44%.

• Standalone EBITDA margin for Q3 improved to 26.09% from 24.25% YoY; consolidated EBITDA margin at 22.15%, up from 19.87%.

• Standalone net profit for nine months FY26 was Rs. 870.23 crores (up 22%); consolidated net profit was Rs. 842.05 crores (up 26%).

• Standalone EPS for Q3 FY26 was Rs. 11.96 (up 13%); consolidated EPS was Rs. 12.86 (up 31%).

• Material cost to sales ratio improved by 3.36 percentage points YoY for nine months, driven by product mix and higher-margin business growth.

Outlook and guidance

• Expecting 10%-12% annual growth in promotional branded, generic, API, and domestic businesses over the next 3-5 years.

• EBITDA margin (ex-Unichem) expected to improve by 1.5% per year if top-line growth sustains at 10%-12%.

• Unichem's top-line expected to grow 8%-10% annually, with EBITDA margin targeted at 15% in 2-3 years and 20% as filings mature.

• Management highlighted continued growth in both domestic and export markets, with strong performance in branded and generics segments.